Please login to the form below

Not currently logged in
Email:
Password:

Nycomed and Orion in Easyhaler deal

Nycomed has agreed a deal with Orion Corporation for the co-marketing of Easyhaler combination products for the treatment of asthma and chronic obstructive pulmonary disease (COPD)

Nycomed has entered into an agreement with Orion Corporation for the co-marketing of Easyhaler combination products for the treatment of asthma and COPD in the major European countries, and an exclusive license and distribution arrangement for the Middle East and North Africa region (MENA). 

Orion is developing a budesonide-formoterol formulation that combines budesonide as an anti-inflammatory agent and formoterol as a long-acting bronchodilator. Orion has another Easyhaler research programme in progress to develop a fluticasone-salmeterol formulation. In this formulation fluticasone acts as an anti-inflammatory agent and salmeterol acts as a long-acting bronchodilator. 

The co-marketing area – in which both companies present their own product brands under the Easyhaler umbrella brand – covers the major European countries including Austria, the Benelux countries, France, Germany, Greece, Italy, Poland, Portugal, Spain and Switzerland. Orion will retain exclusive marketing rights for the Nordic countries, the UK and Eastern Europe, where the company is currently promoting single molecule Easyhaler products. Orion will exclusively manufacture the Easyhaler combination products covered by the agreement.

Dr. Liisa Hurme, senior vice-president of Orion's proprietary products division, said: “The collaboration creates a momentum for Easyhaler products in Europe and strengthens Orion's strategic objective to become a stronger player in the field of respiratory medication.”

Guido Oelkers, executive vice-president of commercial operations, Nycomed, added: “We see great potential in these high-quality Easyhaler products in major European countries and the MENA region. They will significantly enhance Nycomed's fast-growing Respiratory portfolio.”

8th August 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics